List of Excipients in Branded Drug VYNDAQEL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pfizer Laboratories Div Pfizer Inc	VYNDAQEL	tafamidis meglumine	0069-1975	AMMONIA	2026-12-19
Pfizer Laboratories Div Pfizer Inc	VYNDAQEL	tafamidis meglumine	0069-1975	FD&C BLUE NO. 1	2026-12-19
Pfizer Laboratories Div Pfizer Inc	VYNDAQEL	tafamidis meglumine	0069-1975	FERRIC OXIDE YELLOW	2026-12-19
Pfizer Laboratories Div Pfizer Inc	VYNDAQEL	tafamidis meglumine	0069-1975	GELATIN	2026-12-19
Pfizer Laboratories Div Pfizer Inc	VYNDAQEL	tafamidis meglumine	0069-1975	GLYCERIN	2026-12-19

Vyndaqel Excipient Strategy and Commercial Opportunities in Tafamidis Products

Last updated: September 15, 2026

Vyndaqel is Pfizer’s tafamidis meglumine softgel for transthyretin-mediated amyloidosis. Its commercial position is built on a differentiated formulation, a simplified dosing alternative in Vyndamax, orphan-disease pricing, and manufacturing know-how in softgel delivery. The principal excipient opportunities are gelatin capsules, plasticizers, pigments, solubilization systems, and alternative capsule technologies that could reduce cost or support generic and regional products.

What is Vyndaqel and how does its formulation work?

Vyndaqel contains tafamidis meglumine, while Vyndamax contains tafamidis in the free-acid form. Both products deliver the active tafamidis moiety, which stabilizes transthyretin tetramers and reduces dissociation associated with transthyretin amyloidosis.

Product	Active ingredient	Strength	Dosage form	FDA approval
Vyndaqel	Tafamidis meglumine	20 mg	Soft gelatin capsule	2019
Vyndamax	Tafamidis	61 mg	Soft gelatin capsule	2019

Vyndaqel is administered as four 20 mg capsules once daily. Vyndamax is administered as one 61 mg capsule once daily. Pfizer’s labeling states that the two products provide equivalent tafamidis exposure at the approved doses, despite the different salt and strength presentations (FDA, 2024a; FDA, 2024b).

The formulation strategy solves two technical problems:

1. Tafamidis has limited aqueous solubility.
2. The commercial dose must be delivered in a compact, stable oral dosage form suitable for chronic use.

A softgel can contain a nonaqueous fill that improves dose uniformity and supports dissolution without requiring a large tablet or multiple excipient-heavy solid doses.

What excipients are used in Vyndaqel?

Vyndaqel’s listed inactive ingredients are primarily associated with the softgel shell and capsule appearance.

Vyndaqel excipients

The Vyndaqel 20 mg soft capsule contains:

• Gelatin
• Glycerin
• Sorbitol
• Titanium dioxide
• Yellow iron oxide

The capsule shell uses gelatin as the structural polymer. Glycerin and sorbitol act as plasticizing and moisture-management agents. Titanium dioxide and yellow iron oxide provide opacity and color identification (FDA, 2024a).

Vyndamax excipients

The Vyndamax 61 mg soft capsule contains:

• Gelatin
• Glycerin
• Sorbitol
• Titanium dioxide
• Red iron oxide
• Polysorbate 80

Vyndamax uses a different color system and includes polysorbate 80 in the listed formulation. The excipient difference reflects product-specific formulation development rather than a change in the pharmacologic target (FDA, 2024b).

Excipient	Likely technical function	Commercial relevance
Gelatin	Softgel shell former	High; requires pharmaceutical-grade supply and controlled microbiological quality
Glycerin	Plasticizer and humectant	High; affects shell elasticity and long-term stability
Sorbitol	Plasticizer and moisture-control agent	High; influences brittleness, water activity, and capsule integrity
Titanium dioxide	Opacifier and whitening agent	Medium to high; regulatory scrutiny varies by jurisdiction
Iron oxide	Colorant and product identification	Medium; enables product differentiation
Polysorbate 80	Surfactant and solubilization aid	High for formulation compatibility and oxidation control

Why is the softgel platform commercially important?

The softgel platform creates a manufacturing barrier that is more complex than a conventional immediate-release tablet. Critical process parameters include fill viscosity, shell ribbon thickness, gelatin bloom strength, sealing temperature, drying conditions, residual moisture, capsule weight, and leakage control.

For tafamidis, these parameters matter because the product is intended for long-term daily administration in an older patient population. Product quality risks include:

• Shell brittleness or deformation
• Fill migration into the gelatin shell
• Oxidative degradation of formulation components
• Inconsistent capsule weight
• Dissolution variability
• Cross-linking or hardening of the gelatin shell
• Color instability
• Capsule leakage during storage

The excipient system is therefore part of the product’s manufacturing know-how. A competitor can reproduce the active pharmaceutical ingredient but still face development risk in matching softgel performance, stability, and bioequivalence.

What excipient strategies could support tafamidis competition?

Reformulated softgel products

The most direct opportunity is a softgel using alternative suppliers or grades of gelatin, glycerin, sorbitol, iron oxide, titanium dioxide, and polysorbate 80. This approach can preserve the dosage form while reducing dependence on Pfizer’s exact supply chain.

Potential development objectives include:

• Lower cost of goods
• Improved shell stability
• Reduced oxygen permeability
• Improved dissolution
• Greater tolerance to heat and humidity
• Removal or replacement of jurisdictionally restricted colorants
• More efficient filling and drying

The primary regulatory risk is that changes to the fill or shell may alter dissolution, stability, or bioequivalence.

Non-gelatin softgels

Vegetarian or non-animal softgel shells based on modified starch, carrageenan, pullulan, or hydrocolloid blends could address religious, dietary, and market-access requirements. These systems can be commercially attractive in parts of Asia, the Middle East, and markets where animal-derived gelatin creates procurement or labeling concerns.

The technical barrier is higher than with conventional gelatin because non-gelatin shells can have different:

• Moisture permeability
• Seal strength
• Drying behavior
• Oxygen transmission
• Mechanical strength
• Compatibility with hydrophobic fills

A non-gelatin product may require a new stability package and separate process validation.

Hard capsules or liquid-filled hard capsules

A liquid-filled hard capsule could avoid some softgel equipment requirements. It may use a gelatin or hydroxypropyl methylcellulose shell and a liquid or semi-solid fill containing solubilizers, surfactants, and lipid excipients.

This strategy could reduce manufacturing complexity, but the product would need to demonstrate acceptable dissolution and bioavailability. Capsule-shell compatibility and leakage control remain important.

Amorphous or self-emulsifying systems

Tafamidis developers may investigate:

• Self-emulsifying drug delivery systems
• Lipid-based formulations
• Amorphous solid dispersions
• Co-crystals
• Surfactant-enhanced fills
• Nanoparticle or micronized suspensions

These technologies could reduce capsule size or enable tablet development. They also introduce new risks, including precipitation after dilution, excipient oxidation, drug-excipient interactions, and food-effect changes.

The most commercially realistic approach is likely an optimized softgel or liquid-filled capsule rather than a high-risk nanotechnology platform.

What is the commercial opportunity for excipient suppliers?

The Vyndaqel franchise creates demand across several excipient categories.

Pharmaceutical gelatin

Gelatin suppliers can compete on bloom strength, viscosity, microbiological control, traceability, and low-endotoxin performance. Supply assurance is commercially important because softgel production depends on consistent shell properties.

Animal-origin controls also matter. Suppliers with robust bovine, porcine, or fish-derived sourcing documentation can support regional registration and labeling requirements.

Plasticizers and moisture-control agents

Glycerin and sorbitol are commodity excipients, but softgel manufacturers value consistency in:

• Water content
• Impurity profile
• Viscosity
• Microbial quality
• Batch-to-batch performance

Premium opportunity exists where an excipient supplier can demonstrate better shell robustness, reduced leakage, or longer stability under tropical conditions.

Surfactants and solubilizers

Polysorbate 80 and alternative surfactants have higher technical value because they can affect drug solubilization, oxidation, and bioavailability. Suppliers may position:

• Low-peroxide polysorbate 80
• Stabilized surfactant grades
• Alternative nonionic surfactants
• Lipid excipient systems
• Self-emulsifying formulation platforms

Low-peroxide materials are particularly relevant for formulations containing oxidation-sensitive components.

Colorants and opacifiers

Iron oxides and titanium dioxide support visual identification, but regulatory requirements vary. Titanium dioxide restrictions in certain jurisdictions create an opportunity for alternative opacifiers or pigment systems.

Potential replacements include:

• Calcium carbonate
• Starch-based opacifiers
• Alternative mineral pigments
• Colored shell systems with reduced titanium dioxide content

Any substitution must preserve appearance, dose-form identification, photostability, and regulatory acceptability.

How does Vyndaqel compare with Vyndamax?

Vyndamax has a stronger adherence proposition because it delivers the daily dose in one capsule. Vyndaqel requires four capsules per dose.

Commercial factor	Vyndaqel	Vyndamax
Dose frequency	Once daily	Once daily
Capsules per dose	Four	One
Active form	Tafamidis meglumine	Tafamidis
Strength	20 mg	61 mg
Patient convenience	Lower	Higher
Excipient profile	Gelatin, glycerin, sorbitol, pigments	Same core shell system plus polysorbate 80 and different pigment profile
Competitive target	Multiple-capsule substitution	Direct one-capsule substitution
Reformulation opportunity	Dose consolidation	Cost reduction and shell optimization

Vyndamax is likely the more important reference product for future generic development because it is the simpler patient presentation and the stronger commercial benchmark. A competitor that matches Vyndamax’s one-capsule regimen has a clearer substitution proposition than one reproducing Vyndaqel’s four-capsule regimen.

What FDA regulatory issues affect tafamidis excipient opportunities?

Vyndaqel and Vyndamax are FDA-approved small-molecule products, not biologics. Biosimilar pathways do not apply. Competitive products would generally pursue an abbreviated new drug application or a 505(b)(2) pathway, depending on the formulation, reference product, and extent of clinical bridging required.

ANDA pathway

An ANDA applicant would need to address:

• Pharmaceutical equivalence
• Bioequivalence
• Dosage-form equivalence
• Dissolution
• Stability
• Impurity controls
• Manufacturing-process validation
• Container-closure compatibility

Excipient changes are possible, but they cannot create clinically meaningful differences in safety, efficacy, or absorption.

505(b)(2) pathway

A 505(b)(2) application could be relevant for:

• A different dosage form
• A new non-gelatin shell
• A modified-release or improved-solubility formulation
• A lower capsule burden
• A product with a new administration or stability profile

The commercial advantage would depend on whether the formulation provides a legally protectable clinical or pharmaceutical benefit.

FDA inactive-ingredient considerations

A novel excipient or an excipient used above established exposure levels can increase regulatory burden. Established compendial excipients are commercially preferable because they reduce toxicology and safety-review requirements.

Key regulatory considerations include:

• FDA Inactive Ingredient Database precedent
• Maximum daily exposure
• Route and dosage-form history
• Residual solvents
• Elemental impurities
• Nitrosamine and peroxide risk
• Animal-origin controls
• Allergen and labeling requirements

What patents and exclusivity protect Vyndaqel?

Vyndaqel’s protection is likely distributed across compound, formulation, method-of-use, manufacturing, and regulatory exclusivity rights. Exact patent scope and expiration depend on the jurisdiction, patent-term adjustments, pediatric extensions, terminal disclaimers, and Orange Book listings in force.

The relevant protection categories are:

Protection category	Strategic purpose
Tafamidis compound patents	Protect the active molecule or chemical form
Salt and crystal-form patents	Protect tafamidis meglumine or solid-state properties
Formulation patents	Protect softgel composition, excipient combinations, or dissolution performance
Method-of-use patents	Protect treatment of transthyretin amyloidosis and related indications
Manufacturing patents	Protect synthesis, purification, or encapsulation processes
Regulatory exclusivity	Delay certain abbreviated applications independent of patent scope

Vyndaqel and Vyndamax are listed in the FDA Orange Book, but Orange Book status should be checked against the current FDA publication before making a launch or litigation decision (FDA, 2024c). Patent listings can change through delisting, correction, expiration, pediatric extensions, or court-related events.

Because tafamidis is a small molecule, biosimilar risk is not relevant. The commercial risk comes from generic or 505(b)(2) competition, not from biosimilar entry.

What generic launch risks exist for Vyndaqel and Vyndamax?

Generic developers face several risks beyond active-ingredient synthesis.

Bioequivalence risk

Tafamidis formulations may show sensitivity to:

• Fill composition
• Particle size
• Solubilization
• Capsule-shell permeability
• Food conditions
• Dissolution method
• Manufacturing scale

A generic softgel that appears compositionally similar may still fail comparative dissolution or pharmacokinetic criteria.

CMC risk

The dosage form requires specialized equipment and process expertise. Important risks include:

• Gelatin-shell variability
• Long drying cycles
• Moisture migration
• Fill-shell interaction
• Capsule leakage
• Equipment scale-up
• Stability failures under accelerated conditions

Legal risk

An applicant may face Paragraph IV litigation if it certifies that listed patents are invalid, unenforceable, or not infringed. A Paragraph IV filing can trigger patent litigation and a potential 30-month stay of FDA approval under the Hatch-Waxman framework, subject to statutory conditions.

The key legal battlegrounds are likely to include formulation claims, dosing claims, salt or solid-state claims, and method-of-use claims. A generic using a materially different excipient system may reduce formulation infringement risk but increase regulatory and bioequivalence risk.

Which companies could compete in tafamidis excipients and manufacturing?

The competitive landscape spans three groups:

1. Softgel contract manufacturers with encapsulation and drying capacity.
2. Pharmaceutical excipient suppliers.
3. Generic and specialty-drug companies with cardiometabolic or rare-disease portfolios.

Relevant capabilities include:

• Pharmaceutical softgel manufacturing
• Low-peroxide lipid and surfactant systems
• Non-gelatin capsule technology
• Colorant and opacifier substitution
• Stability enhancement
• Global CMC support
• ANDA or 505(b)(2) development

Companies with existing softgel infrastructure have an advantage over tablet-focused generic manufacturers. The strongest commercial position belongs to developers that can combine a Vyndamax-compatible one-capsule product with a validated low-cost fill and a robust supply chain.

How large is the commercial opportunity?

Pfizer reported strong growth for Vyndaqel family products, driven by increasing diagnosis and treatment of transthyretin amyloidosis and wider use in cardiomyopathy. Pfizer’s annual reporting groups Vyndaqel, Vyndamax, and related tafamidis products as a major growth franchise (Pfizer, 2024).

The commercial opportunity has several layers:

• Premium generic entry after relevant patent barriers expire
• Regional products using alternative capsule materials
• Contract manufacturing of tafamidis softgels
• Excipient substitution where titanium dioxide or animal gelatin creates market restrictions
• Improved-adherence products using one capsule per day
• Formulation licensing for low-solubility tafamidis products
• Emerging-market supply at lower cost

A generic entrant would likely target Vyndamax first because one capsule reduces patient burden and simplifies commercial messaging. Vyndaqel remains relevant in markets where the 20 mg presentation is established, priced differently, or protected by local registration strategy.

Key Takeaways

• Vyndaqel contains tafamidis meglumine in a four-capsule daily softgel regimen.
• Vyndamax contains tafamidis in a one-capsule 61 mg softgel regimen.
• The core excipient system is gelatin, glycerin, sorbitol, titanium dioxide, and iron oxide, with polysorbate 80 listed for Vyndamax.
• The highest-value excipient opportunities involve softgel shell performance, low-peroxide surfactants, non-gelatin capsules, and alternative opacifiers.
• Softgel manufacturing know-how creates a meaningful technical barrier to generic entry.
• Tafamidis has small-molecule generic risk, not biosimilar risk.
• Vyndamax is the stronger commercial target because its one-capsule regimen is easier to match and market.
• Excipient substitutions may reduce patent exposure but can increase bioequivalence, stability, and CMC risk.
• Current Orange Book listings, patent status, and Paragraph IV activity must be evaluated before making a launch forecast.

FAQs

Can Vyndaqel be reformulated as a tablet?

Yes. A tablet, hard capsule, or amorphous dispersion could be developed, but the applicant would need to establish acceptable dissolution, bioavailability, stability, and regulatory comparability.

Are Vyndaqel excipients patent-protected?

Individual commodity excipients such as gelatin, glycerin, and sorbitol are generally not the commercial protection focus. Protection may instead cover specific combinations, ratios, capsule structures, manufacturing processes, or performance characteristics.

Is Vyndamax easier to genericize than Vyndaqel?

Vyndamax has a simpler one-capsule regimen, but its formulation may require tighter control of solubilization and fill composition. The lower capsule count improves commercial appeal but does not eliminate CMC or bioequivalence risk.

Could a vegetarian tafamidis capsule compete with Vyndaqel?

Yes. A non-gelatin capsule could address regional preferences and market-access requirements. The developer would need to validate shell integrity, moisture transmission, dissolution, stability, and manufacturing reproducibility.

What is the strongest commercial opportunity in the Vyndaqel franchise?

The strongest opportunity is a one-capsule tafamidis product with Vyndamax-equivalent performance, lower manufacturing cost, broad geographic registration, and a capsule shell that avoids animal-origin or restricted-colorant barriers.

References

1. U.S. Food and Drug Administration. (2024a). Vyndaqel (tafamidis meglumine) capsules: Prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024b). Vyndamax (tafamidis) capsules: Prescribing information. FDA.

3. U.S. Food and Drug Administration. (2024c). Approved drug products with therapeutic equivalence evaluations. FDA.

4. Pfizer Inc. (2024). 2023 annual report. Pfizer.

5. U.S. Food and Drug Administration. (2023). Inactive ingredient database. FDA.